Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.54 Million EUR | -48.75% |
| 2022 | 37.99 Million EUR | 99.03% |
| 2021 | 19.08 Million EUR | -38.01% |
| 2020 | 30.79 Million EUR | 1.25% |
| 2019 | 30.41 Million EUR | 9.1% |
| 2018 | 27.87 Million EUR | 27.02% |
| 2017 | 21.94 Million EUR | 5.91% |
| 2016 | 20.71 Million EUR | 36.29% |
| 2015 | 15.2 Million EUR | 1.58% |
| 2014 | 14.96 Million EUR | 2.97% |
| 2013 | 14.53 Million EUR | -20.23% |
| 2012 | 18.21 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 5.22 Million EUR | 0.0% |
| 2023 Q4 | 5.36 Million EUR | 0.0% |
| 2023 Q3 | 5.36 Million EUR | 2.72% |
| 2023 FY | 19.47 Million EUR | -48.75% |
| 2023 Q1 | 4.92 Million EUR | -65.06% |
| 2023 Q2 | 5.22 Million EUR | 6.12% |
| 2022 Q2 | 3.43 Million EUR | -30.21% |
| 2022 Q3 | 14.08 Million EUR | 309.68% |
| 2022 Q4 | 14.08 Million EUR | 0.0% |
| 2022 FY | 37.99 Million EUR | 99.03% |
| 2022 Q1 | 4.92 Million EUR | -37.63% |
| 2021 FY | 19.08 Million EUR | -38.01% |
| 2021 Q3 | 4.95 Million EUR | -40.18% |
| 2021 Q4 | 7.9 Million EUR | 59.42% |
| 2021 Q1 | 4.57 Million EUR | -63.22% |
| 2021 Q2 | 8.28 Million EUR | 81.11% |
| 2020 Q2 | 15 Million EUR | 88.23% |
| 2020 Q1 | 7.96 Million EUR | 150.68% |
| 2020 Q4 | 12.43 Million EUR | 32.02% |
| 2020 Q3 | 9.41 Million EUR | -37.2% |
| 2020 FY | 30.79 Million EUR | 1.25% |
| 2019 Q1 | 7.2 Million EUR | 34.4% |
| 2019 Q4 | 3.17 Million EUR | -55.29% |
| 2019 Q2 | 7.58 Million EUR | 5.25% |
| 2019 FY | 30.41 Million EUR | 9.1% |
| 2019 Q3 | 7.11 Million EUR | -6.21% |
| 2018 Q2 | 5.74 Million EUR | -1.36% |
| 2018 Q3 | 6.87 Million EUR | 19.55% |
| 2018 FY | 27.87 Million EUR | 27.02% |
| 2018 Q4 | 5.36 Million EUR | -22.01% |
| 2018 Q1 | 5.82 Million EUR | -28.08% |
| 2017 FY | 21.94 Million EUR | 5.91% |
| 2017 Q4 | 8.1 Million EUR | 86.15% |
| 2017 Q3 | 4.35 Million EUR | -11.25% |
| 2017 Q2 | 4.9 Million EUR | 9.29% |
| 2017 Q1 | 4.48 Million EUR | -29.4% |
| 2016 Q2 | 198.99 Thousand EUR | -89.59% |
| 2016 Q3 | 6.3 Million EUR | 3066.85% |
| 2016 Q1 | 1.91 Million EUR | -64.47% |
| 2016 FY | 20.71 Million EUR | 36.29% |
| 2016 Q4 | 6.35 Million EUR | 0.87% |
| 2015 Q2 | 3.57 Million EUR | -24.35% |
| 2015 FY | 15.2 Million EUR | 1.58% |
| 2015 Q4 | 5.37 Million EUR | 30.69% |
| 2015 Q3 | 4.11 Million EUR | 15.1% |
| 2015 Q1 | 4.72 Million EUR | 11.2% |
| 2014 Q3 | 4.51 Million EUR | 26.35% |
| 2014 Q4 | 4.25 Million EUR | -5.78% |
| 2014 Q2 | 3.57 Million EUR | 35.68% |
| 2014 Q1 | 2.63 Million EUR | -33.57% |
| 2014 FY | 14.96 Million EUR | 2.97% |
| 2013 Q4 | 3.96 Million EUR | 17.5% |
| 2013 Q3 | 3.37 Million EUR | 3.37% |
| 2013 Q2 | 3.26 Million EUR | -2.07% |
| 2013 FY | 14.53 Million EUR | -20.23% |
| 2013 Q1 | 3.33 Million EUR | -72.71% |
| 2012 Q3 | 3.01 Million EUR | 0.0% |
| 2012 FY | 18.21 Million EUR | 0.0% |
| 2012 Q4 | 12.2 Million EUR | 305.35% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -437.676% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 76.332% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -7747.902% |
| SQZ Biotechnologies Company | 85.61 Million USD | 76.01% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -604.333% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 30.498% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 44.867% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1267.602% |
| Marizyme, Inc. | 19.23 Million USD | -6.758% |
| Genus plc | 147.7 Million USD | 86.093% |
| Pharming Group N.V. | 225.49 Million USD | 90.891% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -902.585% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1431.071% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -146.313% |
| ContraFect Corporation | 56.88 Million USD | 63.895% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1289.009% |
| IMV Inc. | 37.7 Million USD | 45.531% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -636.107% |
| ONE Bio Corp. | 6.44 Million USD | -218.751% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 76.101% |
| Mesoblast Limited | 5.9 Million USD | -248.018% |
| MultiCell Technologies, Inc. | 567.42 USD | -3619793.553% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 16.893% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.511% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -5172.534% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -681.725% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -317.657% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1966.02% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1067.259% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -205.745% |
| Skye Bioscience, Inc. | 13.54 Million USD | -51.614% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1001.713% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -133.961% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 82260.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -365.9% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -307.374% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -28.293% |
| Accustem Sciences Inc. | 3.74 Million USD | -448.257% |
| EV Biologics, Inc. | 531.96 Thousand USD | -3761.178% |
| Q BioMed Inc. | 3.43 Million USD | -497.679% |
| GB Sciences, Inc. | 1.42 Million USD | -1345.961% |
| Alpha Cognition Inc. | 9.7 Million USD | -111.63% |
| CSL Limited | 3.44 Billion USD | 99.404% |
| Agentix Corp. | 1.37 Million USD | -1397.351% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 79.321% |
| Enzolytics Inc. | 2.17 Million USD | -842.415% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | -61.58% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -462.631% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1019.288% |
| argenx SE | 1.53 Billion USD | 98.661% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 64.241% |
| HST Global, Inc. | 140.9 Thousand USD | -14476.99% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1867.433% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1725.924% |
| Halberd Corporation | 74.84 Thousand USD | -27344.483% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -754.077% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -503.234% |
| Zenith Capital Corp. | 8.94 Million USD | -129.677% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1200.531% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -736.552% |
| AVAX Technologies, Inc. | 7.31 Million USD | -180.975% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -11876.048% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -969.287% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -117803.679% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -732.671% |
| Helix BioMedix, Inc. | 1.97 Million USD | -941.564% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -89.013% |
| Kadimastem Ltd | 2.41 Million USD | -752.243% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 10.598% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -11217.74% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1438.08% |
| LadRx Corporation | 3.81 Million USD | -438.854% |
| Cell Source, Inc. | 4.32 Million USD | -374.875% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -4843.691% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2124.123% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2124.123% |
| Affymax, Inc. | 39.38 Million USD | 47.849% |
| Mobile Lads Corp. | 554.54 Thousand USD | -3603.931% |
| Itoco Inc. | 919.14 Thousand USD | -2134.69% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -384.615% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1735.567% |
| International Stem Cell Corporation | 5.27 Million USD | -289.679% |
| CytoDyn Inc. | 18.05 Million USD | -13.745% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -81508.328% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -9233.055% |
| Qrons Inc. | 643.67 Thousand USD | -3091.041% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1346.691% |
| SYBLEU INC | 160.87 Thousand USD | -12667.597% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -821.126% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2993.373% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1030.858% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -38918.274% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -100868.392% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 43.363% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1169.468% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2691.387% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -560.238% |
| Neutra Corp. | 243.82 Thousand USD | -8324.213% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -17.661% |
| PureTech Health plc | 144.59 Million USD | 85.795% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -0.245% |
| IXICO plc | 4.7 Million USD | -336.371% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -133.489% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 82.556% |
| CSL Limited | 3.89 Billion USD | 99.472% |
| Cellectis S.A. | 97.32 Million USD | 78.894% |